{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:23:58Z","timestamp":1787181838132,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56380-1","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:13:41Z","timestamp":1780686821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absence of co-occurrence between HER2 amplification and dMMR\/MSI in a large multicentric colorectal cancer cohort"],"prefix":"10.1038","volume":"16","author":[{"given":"Annalice","family":"Gandini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carmisciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pirrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Amatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bonazzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Piscazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Costanza","family":"Aquilano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Sciallero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"56380_CR1","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch, S. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res. 20, 5322\u20135330 (2014).","journal-title":"Clin. Cancer Res."},{"key":"56380_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02527-x","author":"S Nakamori","year":"2024","unstructured":"Nakamori, S. et al. Clinicopathological characteristics of Lynch-like syndrome. Int. J. Clin. Oncol. https:\/\/doi.org\/10.1007\/s10147-024-02527-x (2024).","journal-title":"Int. J. Clin. Oncol."},{"key":"56380_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231170473","volume":"16","author":"B Cervantes","year":"2024","unstructured":"Cervantes, B., Andr\u00e9, T. & Cohen, R. Deficient mismatch repair\/microsatellite unstable colorectal cancer: Therapeutic advances and questions. Ther. Adv. Med. Oncol. 16, 17588359231170473 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"56380_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.20.01600","volume":"39","author":"R Cohen","year":"2021","unstructured":"Cohen, R. et al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: An ACCENT pooled analysis of 12 adjuvant trials. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 39, 642\u2013651 (2021).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"56380_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974793","volume":"13","author":"H Hua","year":"2022","unstructured":"Hua, H. et al. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. Front. Immunol. 13, 974793 (2022).","journal-title":"Front. Immunol."},{"key":"56380_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/bjc.2015.160","volume":"112","author":"TT Sepp\u00e4l\u00e4","year":"2015","unstructured":"Sepp\u00e4l\u00e4, T. T. et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br. J. Cancer 112, 1966\u20131975 (2015).","journal-title":"Br. J. Cancer"},{"key":"56380_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fon-2022-1249","volume":"20","author":"E Elez","year":"2024","unstructured":"Elez, E. et al. SEAMARK: Phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAF V600E-mutant mCRC. Future Oncol. 20, 653\u2013663 (2024).","journal-title":"Future Oncol."},{"key":"56380_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.005","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005 (2024).","journal-title":"Ann. Oncol."},{"key":"56380_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496\u2013508 (2023).","journal-title":"Lancet Oncol."},{"key":"56380_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/oncolo\/oyad200","volume":"28","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T. S. et al. Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: A systematic literature review and meta-analysis of clinical outcomes. Oncologist 28, 885\u2013893 (2023).","journal-title":"Oncologist"},{"key":"56380_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00226","volume":"3","author":"K Raghav","year":"2019","unstructured":"Raghav, K. et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis. Oncol. 3, 1\u201313 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"56380_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1053\/j.gastro.2024.10.046","volume":"168","author":"C Pilati","year":"2025","unstructured":"Pilati, C. et al. ERBB2 comprehensive profiling and prognostication in stage III colon cancer: Findings from PETACC8 and IDEA-France cohorts. Gastroenterology 168, 714-724.e4 (2025).","journal-title":"Gastroenterology"},{"key":"56380_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman, S. D. et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 238, 562\u2013570 (2016).","journal-title":"J. Pathol."},{"key":"56380_CR14","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/bjc.2014.483","volume":"111","author":"B Ingold Heppner","year":"2014","unstructured":"Ingold Heppner, B. et al. HER2\/neu testing in primary colorectal carcinoma. Br. J. Cancer 111, 1977\u20131984 (2014).","journal-title":"Br. J. Cancer"},{"key":"56380_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62096-x","volume":"14","author":"SM Lee","year":"2024","unstructured":"Lee, S. M. & Oh, H. RAS\/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification. Sci. Rep. 14, 11432 (2024).","journal-title":"Sci. Rep."},{"key":"56380_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini, M. et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat. Rev. Clin. Oncol. 22, 385\u2013407 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"56380_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41431-024-01550-w","volume":"32","author":"FE McRonald","year":"2024","unstructured":"McRonald, F. E. et al. Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: Baseline analysis of the diagnostic pathway. Eur. J. Hum. Genet. 32, 529\u2013538 (2024).","journal-title":"Eur. J. Hum. Genet."},{"key":"56380_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738\u2013746 (2016).","journal-title":"Lancet Oncol."},{"key":"56380_CR19","doi-asserted-by":"publisher","first-page":"S514","DOI":"10.1016\/j.annonc.2025.08.1311","volume":"36","author":"K Raghav","year":"2025","unstructured":"Raghav, K. et al. 737MO trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial. Ann. Oncol. 36, S514\u2013S515 (2025).","journal-title":"Ann. Oncol."},{"key":"56380_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53223-3","volume":"15","author":"S Siena","year":"2024","unstructured":"Siena, S. et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: Biomarker analyses of DESTINY-CRC01. Nat. Commun. 15, 10213 (2024).","journal-title":"Nat. Commun."},{"key":"56380_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/14796694.2024.2441101","volume":"21","author":"JH Strickler","year":"2025","unstructured":"Strickler, J. H. et al. MOUNTAINEER-03 phase III study design: First-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 21, 303\u2013311 (2025).","journal-title":"Future Oncol."},{"key":"56380_CR22","doi-asserted-by":"publisher","first-page":"e1161","DOI":"10.1002\/onco.13786","volume":"26","author":"M-Z Qiu","year":"2021","unstructured":"Qiu, M.-Z. et al. Relationship of HER2 alteration and microsatellite instability status in colorectal adenocarcinoma. Oncologist 26, e1161\u2013e1170 (2021).","journal-title":"Oncologist"},{"key":"56380_CR23","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.2147\/CMAR.S297596","volume":"13","author":"H Luo","year":"2021","unstructured":"Luo, H. et al. HER2 overexpression and mismatch repair deficiency are correlated with malignancy in colorectal cancer. Cancer Manag. Res. 13, 3443\u20133454 (2021).","journal-title":"Cancer Manag. Res."},{"key":"56380_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","volume":"28","author":"E Valtorta","year":"2015","unstructured":"Valtorta, E. et al. Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. Mod. Pathol. 28, 1481\u20131491 (2015).","journal-title":"Mod. Pathol."},{"key":"56380_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.gim.2022.01.014","volume":"24","author":"N Abu-Ghazaleh","year":"2022","unstructured":"Abu-Ghazaleh, N., Kaushik, V., Gorelik, A., Jenkins, M. & Macrae, F. Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis. Genet. Med. 24, 971\u2013985 (2022).","journal-title":"Genet. Med."},{"key":"56380_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","volume":"37","author":"A Latham","year":"2019","unstructured":"Latham, A. et al. Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J. Clin. Oncol. 37, 286\u2013295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"56380_CR27","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1200\/JCO.2009.23.7784","volume":"27","author":"HJ J\u00e4rvinen","year":"2009","unstructured":"J\u00e4rvinen, H. J. et al. Ten years after mutation testing for Lynch syndrome: Cancer incidence and outcome in mutation-positive and mutation-negative family members. J. Clin. Oncol. 27, 4793\u20134797 (2009).","journal-title":"J. Clin. Oncol."},{"key":"56380_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100044","volume":"3","author":"A Puccini","year":"2024","unstructured":"Puccini, A. et al. ItaLynch: An ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients. ESMO Gastrointest. Oncol. 3, 100044 (2024).","journal-title":"ESMO Gastrointest. Oncol."},{"key":"56380_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/CEJ.0000000000000870","volume":"33","author":"A Puccini","year":"2024","unstructured":"Puccini, A. et al. Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: A 10-year experience in a single Italian Cancer Center. Eur. J. Cancer Prev. 33, 355\u2013362 (2024).","journal-title":"Eur. J. Cancer Prev."},{"key":"56380_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann, M. et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52, 797\u2013805 (2008).","journal-title":"Histopathology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56380-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:36:06Z","timestamp":1787178966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56380-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56380"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56380-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9105189\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare the following conflict of interests, all not related to this manuscript:  AG: speaker honoraria by Merck FT: advisory role for AstraZeneca, Daiichi-Sankyo, Bayer APa: consult and Advisory role honoraria by Merck Sharp & Dohme, Bristo-Myers Squibb, Merck Serono, Takeda, Servier, Bayer, Amgen, BeOne, Nordic Pharma, Pierre-Fabre, Natera, Incyte, Astra Zeneca. Research funding by Astra Zeneca, Bayer. Travel Expenses by Merck Sharp & Dohme, Pierre Fabre, Amgen, BeOne. GM: speaker honoraria by Amgen. AA: advisory role honoraria by Amgen and Italfarmaco SSc: Speaker: MSD, Gentili, Novartis, GSK; Travel\/accomodation\/expenses for congresses: Novartis, Gentili; Round Table: ALTEMS-GSK APu: reports consulting or advisory roles for GlaxoSmithKline, Takeda Pharmaceuticals U.S.A, Takeda Italia, Bayer, Daiichi Sankyo Italia, MSD Italia, BeOne, Amgen, Pierre Fabre, Agenus; Speaker Honoraria for Pierre Fabre, Servier, Amgen, Bristol Myers Squibb (BMS), Daiichi Sankyo, MSD, Merck Serono, BeOne, Takeda; Institutional funding from GlaxoSmithKline, Amgen; Travel, Accommodations, Expenses from AstraZeneca, Amgen, Merck Serono, BeOne, Takeda.  All other authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26061"}}